Company
Numinus Wellness Inc.
TSE:NUMI
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
74 stories
Numinus Wellness unveils revamped podcast series with additional hosts and expanded topics
The podcast episodes will span diverse themes, featuring engaging conversations around psychedelics, research and the therapy that makes them powerful agents for lasting change in mental health, Numinus Wellness said
Numinus Wellness launches Ketamine for Chronic and Serious Medical Illness Program
The program will offer ketamine-assisted therapy alongside additional community support, focusing on improving patients’ physical, emotional, mental and spiritual suffering caused by illness
Numinus Wellness develops psilocybin-infused tea bag for use in psychedelic research
The company said that it recognized that solid therapeutic products, such as whole mushrooms or pills, might be unappealing or difficult to use by certain populations, such as people receiving palliative care for serious illnesses
Numinus Wellness announces opening of new clinic with expanded capacity in Montreal
"Expanding our services here is another important step towards improving access to best-in-class and innovative mental healthcare in Quebec, while continuing to expand our clientele and market presence," said Numinus founder and CEO Payton
Numinus Wellness says its Toronto clinic now offering ketamine-assisted therapy
“By offering these additional services, we can help alleviate their distress and improve their quality of life,” Numinus Wellness CEO Payton Nyquvest said
Numinus Wellness updates on integration of Novamind acquisition
"We continue to be pleased with the performance of our recently acquired US clinics - and their continued success in building strong client relationships," Payton Nyquvest, founder and CEO said
Numinus Wellness sees fiscal 3Q revenue rise by 31.8% thanks to new acquisitions Mindspace and the Neurology Centre of Toronto
For the period ended May 31, 2022, the Vancouver-based leader in psychedelics-focused mental healthcare, reported revenue of $0.74 million
Numinus Wellness launches new visual brand identity
"Our new updated identity will be instrumental for Numinus as we expand our market presence, drive increased brand awareness, and, ultimately, advance as a leader in psychedelic-assisted therapy and mental health care across North America,"
Numinus Wellness says piloting program to offer ketamine-assisted psychotherapy as a health benefit for eligible employees
Numinus' Utah-based clinics, Cedar Psychiatry, and HempLucid, a Utah-based provider of premium wellness products, have teamed up to ensure that employees with a mental health diagnosis can access care
Numinus applies for international patent for psychedelics production process
"This application is part of Numinus' long-term IP strategic focus on scalable and sustainable production that advances research, development and delivery of innovative psychedelic-derived formulations in North America and beyond," said Pay
Numinus Wellness completes acquisition of Novamind; announces executive team expansion
The acquisition has positioned the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies, with 13 wellness clinics, four clinical research facilities and a dedicated psychedelics rese
Numinus Wellness says shareholders have approved resolution in connection with the proposed acquisition of Novamind
"This acquisition will position our business as one of the leading integrated mental wellness companies in North America offering Ketamine- and psychedelic-assisted therapies, with 13 wellness clinics, four clinical research sites and a ded
Numinus Wellness granted Health Canada approval for psychedelic-assisted therapy using psilocybin for patient with treatment-resistant depression
The psychedelic-assisted therapy treatment, which the company said has shown a great deal of promise in treating depression in recent clinical trials and studies, will take place at one of Numinus’ Montreal clinics
Numinus Wellness announces concert series exploring role of music in psychedelic-assisted therapy
The events will be hosted in various cities across the United States and Canada, with the first event to take place in Los Angeles on May 21, 2022, at Lighthouse Immersive
Numinus Wellness sees fiscal 2Q revenue soar by 240% thanks to its robust wellness clinic acquisitions
For the three-month period ended February 28, 2022, the Vancouver-based mental healthcare company advancing innovative treatments and psychedelic-assisted therapies reported revenue of $0.8 million
Numinus Wellness strikes deal to acquire US psychedelic healthcare company Novamind for C$26.2M
Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization in the US
Numinus Wellness completes first MDMA administration in PTSD trial sponsored by MAPS
"We are proud of our clinical and research teams who have been and continue to be instrumental in driving MDMA-assisted therapy for PTSD research forward in Canada," said Payton Nyquvest, CEO and founder of the company
Numinus Wellness says its research lab receives new biosecurity license for expansion
The addition will contribute novel data on natural psychedelics, presenting additional intellectual property (IP) opportunities and another revenue driver through contract research services
Numinus Wellness receives Health Canada approval to study Ayahuasca brews and San Pedro cactus for psychedelic research
The company said the license expansion will further position it as a recognized global research centre for natural psychedelic medicines
Numinus Wellness welcomes three key advisors to its new bioscience advisory board
The new bioscience advisory board will contribute strategically to advancing Numinus' IP strategy, including product development and clinical trial activities out of the company's Health Canada-licensed research facility
Numinus Wellness research facility licensed by Health Canada to supply psilocybin mushrooms
Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin
Numinus Wellness sees big jump in revenue in 1Q as Health Canada expands Special Access Program for psychedelic treatment
The mental healthcare company saw its revenue grow by 245% to $0.8 million during the three-month period ended November 30, 2021
Numinus Wellness reports key milestones in MAPS-sponsored MDMA-assisted therapy for PTSD clinical trial
Numinus will host the Canadian sites for MAPPUSX, managed through its two recently acquired, purpose-designed clinics, allowing for quick completion of the Canadian segment of the MAPS-sponsored trial.
Numinus Wellness submits Health Canada application for Phase 1 study of proprietary psilocybin formulation NBIO-01
The formulation has been developed to stably deliver psilocybin and other synergistic compounds and will be studied for safety and bioavailability on 20 healthy volunteers, followed by testing against a comparator on 28 more volunteers
Numinus Wellness hails Health Canada on SAP amendments to expand potential access to psychedelic medicines
The policy amendment allows Canadian physicians to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis
Numinus Wellness ends fiscal 2021 with $1.5M in revenue after Mindspace Wellbeing acquisition
"During the fourth quarter we were focused on building the team, infrastructure, technologies and protocols that will allow us to scale our business over the next several years," founder and CEO Payton Nyquvest said
Numinus Wellness develops proprietary tests for screening psychedelic mushroom compounds
"The testing we've developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry," said the company's science
Numinus Wellness receives conditional approval for listing on the Toronto Stock Exchange
Upon moving up from the TSX Venture Exchange , the company's shares will continue to trade under the symbol NUMI
Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness
Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms
Numinus Wellness says it has secured two new psychedelic clinics in Canada to host key study into MDMA-assisted psychotherapy for PTSD
“We look forward to deepening our collaboration with MAPS while expanding the resources and solutions available to those suffering from PTSD," said Numinus CEO Payton Nyquvest
Numinus Wellness advances Phase 1 trial on its proprietary psilocybin product PSYBINA
The company said the finalized study design and protocol mark a major milestone to investigate natural psilocybin
Numinus upgrades psychedelics lab to increase research service capabilities
The expanded lab will double the size of the company's research footprint and is slated for completion in the summer of 2022
Numinus completes acquisition of Neurology Centre of Toronto
NCT will operate as the "Neurology Centre of Toronto by Numinus" and continue under the leadership of its founder, Dr Evan Lewis
Numinus Wellness closes fiscal 3Q with $63.2M cash pile as its trial advances and strategic push into psychedelic neurology
For the period ended May 31, 2021, the health care company saw revenue of $562,076, up 160% from $216,244 in the same quarter of 2020
Numinus Wellness gets Health Canada approval for study on MDMA-assisted therapy for PTSD
Approval at the federal level means that Numinus can now transition the study into the final stages of training staff, sourcing medication and recruit patients
Numinus Wellness strikes deal to acquire Neurology Centre of Toronto, establishing psychedelic centre of excellence
Numinus said that it plans to expand NCT into a “comprehensive clinical neurology treatment centre” that specializes in psychedelic treatment for neurological disorders
Numinus Wellness files US patent application for its proprietary rapid psilocybin production process
The company said that its proprietary process “dramatically” increases the production of psychoactive fungi species that contain psilocybin
Numinus Wellness brings on five new executives to help support growth across Health, R&D and Bioscience divisions
Numinus told shareholders that the new team will support its aim to expand its clinic network internationally, develop and market psychedelic-assisted psychotherapies and boost laboratory capabilities
Numinus Wellness and Optimi Health submit evidence package to Health Canada for all-natural psilocybin extract
Numinus plans to use the candidate mushroom clone to develop a uniform all-natural psilocybin capsule for use in Optimi's human clinical trials
Numinus Wellness congratulates study team on announcement of results from Phase 3 randomized clinical trial of MDMA-assisted therapy for treatment of severe PTSD
The trial, which involved 90 participants with chronic PTSD, demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with
Numinus Wellness ends 2Q with C$28.5M after closing Mindspace Wellbeing acquisition
Subsequent to the quarter-end, Numinus completed a $40.25 million financing and raised an additional $1.5 million from warrant exercises, putting its current cash balance at around $65 million
Archive
NA Proactive news snapshot: Bragg Gaming, Lexaria Bioscience, FPX Nickel, ESE Entertainment, Fortitude Gold UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Numinus Wellness announces Phase 1 clinical trial of Psilocybin extraction
The trial will enroll 14 human volunteers and assess the safety and psychoactive properties of a psilocybe mushroom product extracted and formulated at the Numinus Bioscience lab in British Columbia
Numinus Wellness closes "bought deal" financing of units for total gross proceeds $40.25M after full exercise of over-allotment option
The over-allotment option saw an additional 4,200,000 units purchased for additional gross proceeds of $5.25 million
Numinus Wellness upsizes 'bought-deal' offering to raise aggregate gross proceeds of $35M, up from initial $30M
The company said the underwriters, Eight Capital and Canaccord Genuity have now agreed to purchase an aggregate of 28,000,000 Numinus units at a price of $1.25 each, up from 24.000 initially
Numinus Wellness is emerging as a clear leader in the booming psychedelics sector
The firm is the only Canadian public company licensed to work with the full range of psychedelics and to produce and extract psilocybin from mushrooms
Numinus Wellness plans expansion of psychedelics research laboratory
It said the 7,500 square foot expansion will "enhance our IP and partnerships strategy, generate more revenue through analytics testing for psychedelics and other contract services, and increase our supply of consistent, safe and effective
Numinus Wellness receives license amendments to strengthen its ability to lead psychedelics research and support the global sector
The company's Bioscience unit recently received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – ketamine and LSD
Numinus Wellness says making good progress in its compassionate access study of psilocybin-assisted motivational enhancement therapy
The company said that it has finalized the PRIME study protocol and appointed co-principal investigators to the study
Numinus Wellness's trial for MDMA-assisted therapy is in pre-implementation stage
The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has successfully transitioned into the 'pre-implementation stage' at Numin
Numinus Wellness closes acquisition of Mindspace Psychology Services, a leader and pioneer in psychedelic programming
The acquisition expands Numinus' presence into Quebec, building on its Vancouver office with two established locations and extensive virtual services as well as insights garnered from a decade of successful clinic management.
Numinus Wellness finishes fiscal 1Q with a strong cash balance to advance psychedelic treatment initiatives
During the three-month period to end November 20, 2020, Numinus generated revenue of C$229,188 and ended the quarter with a cash balance of C$4,915,209